Nscale secures deal for 200,000 NVIDIA GB300 GPUs with Microsoft
Maia Biotechnology, Inc. (NYSE American:MAIA), a small-cap biotechnology company with a market capitalization of approximately $51 million, announced Monday that it presented efficacy data from its Phase 2 THIO-101 clinical trial at the 2025 IASLC World Conference on Lung Cancer. The company prepared a scientific poster highlighting results from the study, which evaluated THIO in combination with the immune checkpoint inhibitor cemiplimab (Libtayo) in patients with advanced non-small cell lung cancer who had previously received at least two standard therapies.
The abstract, titled "Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS," was displayed at the conference on Sunday. Maia Biotechnology stated that the poster will also be available on its website starting Monday. According to InvestingPro data, analysts have set price targets ranging from $10.27 to $14.00 for the stock, which currently trades near $1.54.
The company noted in its statement that the poster contains forward-looking statements and advised investors not to place undue reliance on them. InvestingPro analysis reveals that while MAIA maintains strong liquidity with a current ratio of 2.19, the company faces profitability challenges, with additional insights available to subscribers.
No additional financial or operational updates were disclosed in the filing. The information is based on a press release statement included in the company’s Form 8-K submitted to the Securities and Exchange Commission. The stock has declined 22% year-to-date, though MAIA maintains a favorable cash position relative to its debt obligations.
In other recent news, MAIA Biotechnology announced significant developments regarding its cancer treatment drug, ateganosine. The U.S. Food and Drug Administration granted Fast Track designation for ateganosine, which is aimed at treating non-small cell lung cancer (NSCLC). This designation could potentially speed up the drug’s regulatory approval process. Additionally, MAIA Biotechnology published promising preclinical data on its second-generation ateganosine prodrugs in the journal Nucleic Acids Research. The study highlights the potential of these prodrugs in enhancing cancer treatment and overcoming drug resistance. In further developments, the company has dosed the first patient in Taiwan as part of the THIO-101 Phase 2 trial for advanced NSCLC. This trial is assessing ateganosine in patients who have not responded to previous treatments. These recent advancements underscore MAIA Biotechnology’s ongoing efforts in cancer drug development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.